CXCL9 drives lung adenocarcinoma progression and immunotherapy response via activation of the CXCR3/JAK1/STAT3 signaling pathway. (PubMed, Transl Oncol) - Sep 25, 2026 - "Our findings identify the CXCL9-CXCR3/JAK1/STAT3 axis as a critical regulator of LUAD progression and immunotherapy response, highlighting CXCL9 as a potential prognostic biomarker and therapeutic target in LUAD."
IO biomarker • Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CXCL9 • CXCR3 • JAK1
|
|
Dan Qiu; Jian Zhang; Ning Chang; Qing Ju; Xiangxiang Chen; Ying Zhou; Yong Zhang
|